검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Deucravacitinib |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Takayasu Arteritis (TAK) |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY SLE trial |
MoA Biomarker | biomarker for JAK inhibitor efficacy |
PK/PD Half-life | 10 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview.. Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior. The deuterium kinetic isotope effect (KIE), which strengthens carbon-deuterium bonds, make it possible to improve therapeutic efficacy while… |
Clinical Primary efficacy | ORR 14.8% |
Clinical ORR | 21.6% |
Clinical Result source | ClinicalTrials.gov NCT03934216 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Deucravacitinib |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Takayasu Arteritis (TAK) |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY SLE trial |
MoA Biomarker | biomarker for JAK inhibitor efficacy |
PK/PD Half-life | 10 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview.. Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior. The deuterium kinetic isotope effect (KIE), which strengthens carbon-deuterium bonds, make it possible to improve therapeutic efficacy while… |
Clinical Primary efficacy | ORR 14.8% |
Clinical ORR | 21.6% |
Clinical Result source | ClinicalTrials.gov NCT03934216 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교